Current through Register Vol. 49, No. 9, September, 2024
Section 3.
Definitions
For purposes of this Rule:
A. "Adverse determination" means a
determination by a health carrier or its designee utilization review
organization that an admission, availability of care, continued stay or other
health care service that is a covered benefit has been reviewed and, based upon
the information provided, does not meet the health carrier's requirements for
medical necessity (or substantially equivalent term), appropriateness, health
care setting, level of care or effectiveness, and the requested service or
payment for the service is therefore denied, reduced or terminated.
B. "Ambulatory review" means utilization
review of health care services performed or provided in an outpatient
setting.
C. "Authorized
representative" means:
(1) A person to whom a
covered person has given express written consent to represent the covered
person in an external review;
(2) A
person authorized by law to provide substituted consent for a covered person;
or
(3) A family member of the
covered person or the covered person's treating health care professional only
when the covered person is unable to provide consent.
D. "Best evidence" means evidence based on:
(1) Randomized clinical trials;
(2) If randomized clinical trials are not
available, cohort studies or case-control studies;
(3) If paragraphs (1) and (2) are not
available, case-series; or
(4) If
paragraphs (1), (2) and (3) are not available, expert opinion.
E. "Case-control study" means a
retrospective evaluation of two (2) groups of patients with different outcomes
to determine which specific interventions the patients received.
F. "Case management" means a coordinated set
of activities conducted for individual patient management of serious,
complicated, protracted or other health conditions.
G. "Case-series" means an evaluation of a
series of patients with a particular outcome, without the use of a control
group.
H. "Certification" means a
determination by a health carrier or its designee utilization review
organization that an admission, availability of care, continued stay or other
health care service has been reviewed and, based on the information provided,
satisfies the health carrier's requirements for medical necessity (or
substantially equivalent term), appropriateness, health care setting, level of
care and effectiveness.
I.
"Clinical review criteria" means the written screening procedures,
decision abstracts, clinical protocols and practice guidelines
used by a health carrier to determine the necessity and appropriateness of
health care services.
J.
"Cohort study" means a prospective evaluation of two (2) groups of patients
with only one group of patients receiving a specific intervention(s).
K. "Commissioner" means the Arkansas
Insurance Commissioner.
L.
"Concurrent review" means utilization review conducted during a patient's
hospital stay or course of treatment.
M. "Covered benefits" or "benefits" means
those health care services to which a covered person is entitled under the
terms of a health benefit plan.
N.
"Covered person" means a policyholder, subscriber, enrollee or other individual
participating in a health benefit plan.
O. "Discharge planning" means the formal
process for determining, prior to discharge from a facility, the coordination
and management of the care that a patient receives following discharge from a
facility.
P. "Disclose" means to
release, transfer or otherwise divulge protected health information to any
person other than the individual who is the subject of the protected health
information.
Q. "Emergency medical
condition" means the sudden and, at the time, unexpected onset of a health
condition or illness that requires immediate medical attention, where failure
to provide medical attention would result in a serious impairment to bodily
functions, serious dysfunction of a bodily organ or part, or would place the
person's health in serious jeopardy.
R. "Emergency services" means health care
items and services furnished or required to evaluate and treat an emergency
medical condition.
S.
"Evidence-based standard" means the conscientious, explicit and judicious use
of the current best evidence based on the overall systematic review of the
research in making decisions about the care of individual patients.
T. "Expert opinion" means a belief or an
interpretation by specialists with experience in a specific area about the
scientific evidence pertaining to a particular service, intervention or
therapy.
U. "Facility" means an
institution providing health care services or a health care setting, including
but not limited to, hospitals and other licensed inpatient centers, ambulatory
surgical or treatment centers, skilled nursing centers, residential treatment
centers, diagnostic, laboratory and imaging centers, and rehabilitation and
other therapeutic health settings.
V. "Final adverse determination" means an
adverse determination involving a covered benefit that has been upheld by a
health carrier, or its designee utilization review organization, at the
completion of the health carrier's internal appeal process procedures. If the
health carrier does not have, nor is it required to have, an internal appeal
procedure or utilization review procedure, an adverse determination shall be
considered a final adverse determination.
W. "Health benefit plan" means a policy,
contract, certificate or agreement offered or issued by a health carrier to
provide, deliver, arrange for, pay for or reimburse any of the costs of health
care services.
X. "Health care
professional" means a physician or other health care practitioner licensed,
accredited or certified to perform specified health care services consistent
with state law
Y. "Health care
provider" or "provider" means a health care professional or a
facility.
Z. "Health care services"
means services for the diagnosis, prevention, treatment, cure or relief of a
health condition, illness, injury or disease.
AA. "Health carrier" means an entity subject
to the insurance laws and regulations of Arkansas, or subject to the
jurisdiction of the Commissioner, that contracts or offers to contract to
provide, deliver, arrange for, pay for or reimburse any of the costs of health
care services, including an accident and health insurance company, a health
maintenance organization, a nonprofit hospital and medical service corporation,
or any other entity providing a plan of health insurance, health benefits or
health care services.
BB. "Health
information" means information or data, whether oral or recorded in any form or
medium, and personal facts or information about events or relationships that
relates to:
(1) The past, present or future
physical, mental, or behavioral health or condition of an individual or a
member of the individual's family;
(2) The provision of health care services to
an individual; or
(3) Payment for
the provision of health care services to an individual.
CC. "Independent review organization" means
an entity that conducts independent external reviews of adverse determinations
and final adverse determinations.
DD. "Medical or scientific evidence" means
evidence found in the following sources:
(1)
Peer-reviewed scientific studies published in or accepted for publication by
medical journals that meet nationally recognized requirements for scientific
manuscripts and that submit most of their published articles for review by
experts who are not part of the editorial staff;
(2) Peer-reviewed medical literature,
including literature relating to therapies reviewed and approved by a qualified
institutional review board, biomedical compendia and other medical literature
that meet the criteria of the National Institutes of Health's Library of
Medicine for indexing in Index Medicus (Medline) and Elsevier Science Ltd. for
indexing in Excerpta Medicus (EMBASE);
(3) Medical journals recognized by the
Secretary of Health and Human Services under Section 1861(t)(2) of the federal
Social Security Act;
(4) The
following standard reference compendia:
(a)
The American Hospital Formulary Service-Drug Information;
(b) Drug Facts and Comparisons;
(c) The American Dental Association Accepted
Dental Therapeutics; and
(d) The
United States Pharmacopoeia-Drug Information;
(5) Findings, studies or research conducted
by or under the auspices of federal government agencies and nationally
recognized federal research institutes, including:
(a) The federal Agency for Healthcare
Research and Quality;
(b) The
National Institutes of Health;
(c)
The National Cancer Institute;
(d)
The National Academy of Sciences;
(e) The Centers for Medicare & Medicaid
Services;
(f) The federal Food and
Drug Administration; and
(g) Any
national board recognized by the National Institutes of Health for the purpose
of evaluating the medical value of health care services; or
(6) Any other medical or
scientific evidence that is comparable to the sources listed in paragraphs (1)
through (5).
EE. "NAIC"
means the National Association of Insurance Commissioners.
FF. "Person" means an individual, a
corporation, a partnership, an association, a joint venture, a joint stock
company, a trust, an unincorporated organization, any similar entity or any
combination of the foregoing.
GG.
"Prospective review" means utilization review conducted prior to an admission
or a course of treatment.
HH.
"Protected health information" means health information:
(1) That identifies an individual who is the
subject of the information; or
(2)
With respect to which there is a reasonable basis to believe that the
information could be used to identify an individual.
II. "Randomized clinical trial" means a
controlled, prospective study of patients that have been randomized into an
experimental group and a control group at the beginning of the study with only
the experimental group of patients receiving a specific intervention, which
includes study of the groups for variables and anticipated outcomes over
time.
JJ. "Retrospective review"
means a review of medical necessity (or substantially equivalent term)
conducted after services have been provided to a patient, but does not include
the review of a claim that is limited to an evaluation of reimbursement levels,
veracity of documentation, accuracy of coding or adjudication for
payment.
KK. "Second opinion" means
an opportunity or requirement to obtain a clinical evaluation by a provider
other than the one originally making a recommendation for a proposed health
care service to assess the clinical necessity and appropriateness of the
initial proposed health care service.
LL. "Utilization review" means a set of
formal techniques designed to monitor the use of, or evaluate the clinical
necessity, appropriateness, efficacy, or efficiency of, health care services,
procedures, or settings. Techniques may include ambulatory review, prospective
review, second opinion, certification, concurrent review, case management,
discharge planning, or retrospective review.
MM. "Utilization review organization" means
an entity that conducts utilization review, other than a health carrier
performing a review for its own health benefit plans.
Section 4.
Applicability and
Scope
A. Except as provided in
Subsection (B) of this Section, this Rule shall apply to all health
carriers.
B. The provisions of this
Rule shall not apply to a policy or certificate that provides coverage only for
a specified disease, specified accident or accident-only coverage, credit,
dental, disability income, hospital indemnity, short term limited duration,
long-term care insurance, as defined by Ark. Code Ann. § 23-97-203, vision
care or any other limited supplemental benefit or to a Medicare supplement
policy of insurance, as defined by the Commissioner by regulation, coverage
under a plan through Medicare, Medicaid, or the federal employees health
benefits program, any coverage issued under Chapter 55 of Title 10, U.S. Code
and any coverage issued as supplemental to that coverage, any coverage issued
as supplemental to liability insurance, workers' compensation or similar
insurance, automobile medical-payment insurance or any insurance under which
benefits are payable with or without regard to fault, whether written on a
group blanket or individual basis.
Section
8.
Standard External Review
A.
(1)
Within four (4) months after the date of receipt of a notice of an adverse
determination or final adverse determination pursuant to Section (5) of this
Rule, a covered person or the covered person's authorized representative may
file a request for an external review with the Commissioner.
(2) Within one (1) business day after the
date of receipt of a request for external review pursuant to (A) (1) under this
Section, the Commissioner shall send a copy of the request to the health
carrier.
B. Within five
(5) business days following the date of receipt of the copy of the external
review request from the Commissioner under (A)(2) of this Section, the health
carrier shall complete a preliminary review of the request to determine
whether:
(1) The individual is or was a
covered person in the health benefit plan at the time the health care service
was requested or, in the case of a retrospective review, was a covered person
in the health benefit plan at the time the health care service was
provided;
(2) The health care
service that is the subject of the adverse determination or the final adverse
determination is a covered service under the covered person's health benefit
plan, but for a determination by the health carrier that the health care
service is not covered because it does not meet the health carrier's
requirements for medical necessity ( or substantially equivalent term),
appropriateness, health care setting, level of care or effectiveness;
(3) The covered person has exhausted the
health carrier's internal appeal process unless the covered person is not
required to exhaust the health carrier's internal appeal process pursuant to
Section (7) of this Rule; and
(4)
The covered person has provided all the information and forms required to
process an external review, including the release form provided under Section
(5)(B) of this Rule.
C.
(1) Within one (1) business day after
completion of the preliminary review, the health carrier shall notify the
commissioner and covered person and, if applicable, the covered person's
authorized representative in writing whether:
(a) The request is complete; and
(b) The request is eligible for external
review.
(2) If the
request:
(a) Is not complete, the health
carrier shall inform the covered person and, if applicable, the covered
person's authorized representative and the commissioner in writing and include
in the notice what information or materials are needed to make the request
complete; or
(b) Is not eligible
for external review, the health carrier shall inform the covered person, if
applicable, the covered person's authorized representative and the commissioner
in writing and include in the notice the reasons for its
ineligibility.
(3)
(a) The Commissioner may specify the form for
the health carrier's notice of initial determination under this subsection and
any supporting information to be included in the notice by bulletin, directive
or other publication to health carriers.
(b) The notice of initial determination shall
include a statement informing the covered person and, if applicable, the
covered person's authorized representative that a health carrier's initial
determination that the external review request is ineligible for review may be
appealed to the Commissioner.
(4)
(a) The
Commissioner may determine that a request is eligible for external review
notwithstanding a health carrier's initial determination that the request is
ineligible and require that it be referred for external review.
(b) In making a determination under (4)(a) of
this Section, the
Commissioner's decision shall be made in accordance with the
terms of the covered person's health benefit plan and shall be subject to all
applicable provisions of this Rule.
D.
(1)
Whenever the Commissioner receives a notice that a request is eligible for
external review following the preliminary review conducted pursuant to
subsection (C) under this Section, within one (1) business day after the date
of receipt of the notice, the Commissioner shall:
(a) Assign an independent review organization
from the list of approved independent review organizations compiled and
maintained by the Commissioner pursuant to Section (12) of this Rule to conduct
the external review and notify the health carrier of the name of the assigned
independent review organization; and
(b) Notify in writing the covered person and,
if applicable, the covered person's authorized representative of the request's
eligibility and acceptance for external review.
(2) In reaching a decision, the assigned
independent review organization is not bound by any decisions or conclusions
reached during the health carrier's utilization review process or the health
carrier's internal appeal process.
(3) The Commissioner shall include in the
notice provided to the covered person and, if applicable, the covered person's
authorized representative a statement that the covered person or the covered
person's authorized representative may submit in writing to the assigned
independent review organization within five (5) business days following the
date of receipt of the notice provided pursuant to (D)(1) under this Section
additional information that the independent review organization shall consider
when conducting the external review. The independent review organization is not
required to, but may, accept and consider additional information submitted
after five (5) business days.
E.
(1)
Within five (5) business days after the date of receipt of the notice provided
pursuant to (D)(1) of this Section, the health carrier or its designee
utilization review organization shall provide to the assigned independent
review organization the documents and any information considered in making the
adverse determination or final adverse determination.
(2) Except as provided in (E)(3) under this
Section, failure by the health carrier or its utilization review organization
to provide the documents and information within the time specified in (E)(1) of
this Section shall not delay the conduct of the external review.
(3)
(a) If
the health carrier or its utilization review organization fails to provide the
documents and information within the time specified in (E)(1) of this Section,
the assigned independent review organization may terminate the external review
and make a decision to reverse the adverse determination or final adverse
determination.
(b) Within one (1)
business day after making the decision under (E)(3)(a) of this Section, the
independent review organization shall notify the covered person, if applicable,
the covered person's authorized representative, the health carrier, and the
commissioner.
F.
(1) The
assigned independent review organization shall review all of the information
and documents received pursuant to Subsection (E) under this Section and any
other information submitted in writing to the independent review organization
by the covered person or the covered person's authorized representative
pursuant to (D)(3) of this Section.
(2) Upon receipt of any information submitted
by the covered person or the covered person's authorized representative
pursuant to subsection (D)(3) under this Section, the assigned independent
review organization shall within one (1) business day forward the information
to the health carrier.
G.
(1) Upon
receipt of the information, if any, required to be forwarded pursuant to
subsection (F)(2) of this Section, the health carrier may reconsider its
adverse determination or final adverse determination that is the subject of the
external review.
(2)
Reconsideration by the health carrier of its adverse determination or final
adverse determination pursuant to (G)(1) under this Section shall not delay or
terminate the external review.
(3)
The external review may only be terminated if the health carrier decides, upon
completion of its reconsideration, to reverse its adverse determination or
final adverse determination and provide coverage or payment for the health care
service that is the subject of the adverse determination or final adverse
determination.
(4)
(a) Within one (1) business day after making
the decision to reverse its adverse determination or final adverse
determination, as provided in (G)(3) of this Section, the health carrier shall
notify the covered person, if applicable, the covered person's authorized
representative, the assigned independent review organization, and the
commissioner in writing of its decision.
(b) The assigned independent review
organization shall terminate the external review upon receipt of the notice
from the health carrier sent pursuant to (G)(4)(a) of this Section.
H. In addition to the
documents and information provided pursuant to Subsection (E) under this
Section, the assigned independent review organization, to the extent the
information or documents are available and the independent review organization
considers them appropriate, shall consider the following in reaching a
decision:
(1) The covered person's medical
records;
(2) The attending health
care professional's recommendation;
(3) Consulting reports from appropriate
health care professionals and other documents submitted by the health carrier,
covered person, the covered person's authorized representative, or the covered
person's treating provider;
(4) The
terms of coverage under the covered person's health benefit plan with the
health carrier to ensure that the independent review organization's decision is
not contrary to the terms of coverage under the covered person's health benefit
plan with the health carrier;
(5)
The most appropriate practice guidelines, which shall include applicable
evidence-based standards and may include any other practice guidelines
developed by the federal government, national or professional medical
societies, boards and associations;
(6) Any applicable clinical review criteria
developed and used by the health carrier or its designee utilization review
organization; and
(7) The opinion
of the independent review organization's clinical reviewer or reviewers after
considering paragraphs (H)(1) through (H)(6) of this Section to the extent the
information or documents are available and the clinical reviewer or reviewers
consider appropriate.
I.
(1) Within forty-five (45) days after the
date of receipt of the request for an external review, the assigned independent
review organization shall provide written notice of its decision to uphold or
reverse the adverse determination or the final adverse determination to:
(a) The covered person;
(b) If applicable, the covered person's
authorized representative;
(c) The
health carrier; and
(d) The
commissioner.
(2) The
independent review organization shall include in the notice sent pursuant to
(I)(1) of this Section:
(a) A general
description of the reason for the request for external review;
(b) The date the independent review
organization received the assignment from the commissioner to conduct the
external review;
(c) The date the
external review was conducted;
(d)
The date of its decision;
(e) The
principal reason or reasons for its decision, including what applicable, if
any, evidence-based standards were a basis for its decision;
(f) The rationale for its decision;
and
(g) References to the evidence
or documentation, including the evidence-based standards, considered in
reaching its decision.
(3) Upon receipt of a notice of a decision
pursuant to paragraph (I)(1)
of this Section reversing the adverse determination or final
adverse determination, the health carrier immediately shall approve the
coverage that was the subject of the adverse determination or final adverse
determination.
J. The assignment by the Commissioner of an
approved independent review organization to conduct an external review in
accordance with this section shall be done on a random basis among those
approved independent review organizations qualified to conduct the particular
external review based on the nature of the health care service that is the
subject of the adverse determination or final adverse determination and other
circumstances, including conflict of interest concerns pursuant to Section
(13)(D) of this Rule.
Section
9.
Expedited External Review
A. Except as provided in Subsection (F) under
this Section, a covered person or the covered person's authorized
representative may make a request for an expedited external review with the
Commissioner at the time the covered person receives:
(1) An adverse determination if:
(a) The adverse determination involves a
medical condition of the covered person for which the timeframe for completion
of an expedited internal review of an appeal involving an adverse determination
set forth in the health carrier's internal appeal procedure or utilization
review procedure would seriously jeopardize the life or health of the covered
person or would jeopardize the covered person's ability to regain maximum
function; and
(b) The covered
person or the covered person's authorized representative has filed a request
for an expedited review of an appeal involving an adverse determination as set
forth in the health carrier's internal appeal procedure or utilization review
procedure; or
(2) A
final adverse determination:
(a) If the
covered person has a medical condition where the timeframe for completion of a
standard external review pursuant to Section (8) of this Rule would seriously
jeopardize the life or health of the covered person or would jeopardize the
covered person's ability to regain maximum function; or
(b) If the final adverse determination
concerns an admission, availability of care, continued stay or health care
service for which the covered person received emergency services, but has not
been discharged from a facility.
B.
(1) Upon
receipt of a request for an expedited external review, the Commissioner
immediately shall send a copy of the request to the health carrier.
(2) Immediately upon receipt of the request
pursuant to (B)(1) of this Section, the health carrier shall determine whether
the request meets the reviewability requirements set forth in Section (8)(B) of
this Rule. The health carrier shall immediately notify the Commissioner and the
covered person and, if applicable, the covered person's authorized
representative of its eligibility determination.
(3)
(a) The
Commissioner may specify the form for the health carrier's notice of initial
determination under this subsection and any supporting information to be
included in the notice by bulletin, directive or other publication to health
carriers.
(b) The notice of initial
determination shall include a statement informing the covered person and, if
applicable, the covered person's authorized representative that a health
carrier's initial determination that an external review request is ineligible
for review may be appealed to the Commissioner.
(4)
(a) The
Commissioner may determine that a request is eligible for external review
notwithstanding a health carrier's initial determination that the request is
ineligible and require that it be referred for external review.
(b) In making a determination under (B)(4)(a)
of this Section, the Commissioner's decision shall be made in accordance with
the terms of the covered person's health benefit plan and shall be subject to
all applicable provisions of this Rule.
(5) Upon receipt of the notice that the
request meets the reviewability requirements, the commissioner immediately
shall assign an independent review organization to conduct the expedited
external review from the list of approved independent review organizations
compiled and maintained by the Commissioner pursuant to Section (12) of this
Rule. The Commissioner shall immediately notify the health carrier of the name
of the assigned independent review organization.
(6) In reaching a decision in accordance with
Subsection (E) of this Section, the assigned independent review organization is
not bound by any decisions or conclusions reached during the health carrier's
utilization review process or the health carrier's internal appeal
process.
C. Upon receipt
of the notice from the Commissioner of the name of the independent review
organization assigned to conduct the expedited external review pursuant to
(B)(5) of this Section, the health carrier or its designee utilization review
organization shall provide or transmit all necessary documents and information
considered in making the adverse determination or final adverse determination
to the assigned independent review organization electronically or by telephone
or facsimile or any other available expeditious method.
D. In addition to the documents and
information provided or transmitted pursuant to Subsection (C) of this Section,
the assigned independent review organization, to the extent the information or
documents are available and the independent review organization considers them
appropriate, shall consider the following in reaching a decision:
(1) The covered person's pertinent medical
records;
(2) The attending health
care professional's recommendation;
(3) Consulting reports from appropriate
health care professionals and other documents submitted by the health carrier,
covered person, the covered person's authorized representative or the covered
person's treating provider;
(4) The
terms of coverage under the covered person's health benefit plan with the
health carrier to ensure that the independent review organization's decision is
not contrary to the terms of coverage under the covered person's health benefit
plan with the health carrier;
(5)
The most appropriate practice guidelines, which shall include evidence-based
standards, and may include any other practice guidelines developed by the
federal government, national or professional medical societies, boards and
associations;
(6) Any applicable
clinical review criteria developed and used by the health carrier or its
designee utilization review organization in making adverse determinations;
and
(7) The opinion of the
independent review organization's clinical reviewer or reviewers after
considering (D)(1) through (D)(6) of this Section to the extent the information
and documents are available and the clinical reviewer or reviewers consider
appropriate.
E.
(1) As expeditiously as the covered person's
medical condition or circumstances requires, but in no event more than
seventy-two (72) hours after the date of receipt of the request for an
expedited external review that meets the reviewability requirements set forth
in Section (8)(B) of this Rule, the assigned independent review organization
shall:
(a) Make a decision to uphold or
reverse the adverse determination or final adverse determination; and
(b) Notify the covered person, if applicable,
the covered person's authorized representative, the health carrier, and the
commissioner of the decision.
(2) If the notice provided pursuant to (E)(1)
of this Section was not in writing, within forty-eight (48) hours after the
date of providing that notice, the assigned independent review organization
shall:
(a) Provide written confirmation of
the decision to the covered person, if applicable, the covered person's
authorized representative, the health carrier, and the commissioner;
and
(b) Include the information set
forth in Section (8)(1)(2) of this Rule.
(3) Upon receipt of the notice a decision
pursuant to (E)(1) of this Section reversing the adverse determination or final
adverse determination, the health carrier immediately shall approve the
coverage that was the subject of the adverse determination or final adverse
determination.
F. An
expedited external review may not be provided for retrospective adverse or
final adverse determinations.
G.
The assignment by the Commissioner of an approved independent review
organization to conduct an external review in accordance with this Section
shall be done on a random basis among those approved independent review
organizations qualified to conduct the particular external review based on the
nature of the health care service that is the subject of the adverse
determination or final adverse determination and other circumstances, including
conflict of interest concerns pursuant to Section (13)(D) of this
Rule.
Section 10.
External Review of Experimental or Investigational Treatment Adverse
Determinations
A.
(1) Within four (4) months after the date of
receipt of a notice of an adverse determination or final adverse determination
pursuant to Section (5) of this Rule that involves a denial of coverage based
on a determination that the health care service or treatment recommended or
requested is experimental or investigational, a covered person or the covered
person's authorized representative may file a request for external review with
the Commissioner.
(2)
(a) A covered person or the covered person's
authorized representative may make an oral request for an expedited external
review of the adverse determination or final adverse determination pursuant to
(A)(1) under this Section if the covered person's treating physician certifies,
in writing, that the recommended or requested health care service or treatment
that is the subject of the request would be significantly less effective if not
promptly initiated.
(b) Upon
receipt of a request for an expedited external review, the Commissioner
immediately shall notify the health carrier.
(c)
(i)
Upon notice of the request for expedited external review, the health carrier
immediately shall determine whether the request meets the reviewability
requirements under (B) of this Section. The health carrier shall immediately
notify the Commissioner and the covered person and, if applicable, the covered
person's authorized representative of its eligibility determination.
(ii) The Commissioner may specify the form
for the health carrier's notice of initial determination under (A)(2)(c)(i) of
this Section and any supporting information to be included in the notice by
bulletin, directive or other publication to health carriers.
(iii) The notice of initial determination
under (A)(2)(c)(i) of this Section shall include a statement informing the
covered person and, if applicable, the covered person's authorized
representative that a health carrier's initial determination that the external
review request is ineligible for review may be appealed to the Commissioner.
(d)
(i) The Commissioner may determine that a
request is eligible for external review under (B)(2) of this Section
notwithstanding a health carrier's initial determination the request is
ineligible and require that it be referred for external review.
(ii) In making a determination under
(A)(2)(d)(i) of this Section, the Commissioner's decision shall be made in
accordance with the terms of the covered person's health benefit plan and shall
be subject to all applicable provisions of this Rule.
(e) Upon receipt of the notice that the
expedited external review request meets the reviewability requirements of
(B)(2) under this Section, the Commissioner immediately shall assign an
independent review organization to review the expedited request from the list
of approved independent review organizations compiled and maintained by the
Commissioner pursuant to Section (12) of this Rule and notify the health
carrier of the name of the assigned independent review organization.
(f) At the time the health carrier receives
the notice of the assigned independent review organization pursuant to
(A)(2)(e) of this Section, the health carrier or its designee utilization
review organization shall provide or transmit all necessary documents and
information considered in making the adverse determination or final adverse
determination to the assigned independent review organization electronically or
by telephone or facsimile or any other available expeditious method.
B.
(1) Except for a request for an expedited
external review made pursuant to (A)(2) of this Section, within one (1)
business day after the date of receipt of the request, the Commissioner
receives a request for an external review, the Commissioner shall notify the
health carrier.
(2) Within five (5)
business days following the date of receipt of the notice sent pursuant to
paragraph (1), the health carrier shall conduct and complete a preliminary
review of the request to determine whether:
(a) The individual is or was a covered person
in the health benefit plan at the time the health care service or treatment was
recommended or requested or, in the case of a retrospective review, was a
covered person in the health benefit plan at the time the health care service
or treatment was provided;
(b) The
recommended or requested health care service or treatment that is the subject
of the adverse determination or final adverse determination:
(i) Is a covered benefit under the covered
person's health benefit plan except for the health carrier's determination that
the service or treatment is experimental or investigational for a particular
medical condition; and
(ii) Is not
explicitly listed as an excluded benefit under the covered person's health
benefit plan with the health carrier;
(c) The covered person's treating physician
has certified that one of the following situations is applicable:
(i) Standard health care services or
treatments have not been effective in improving the condition of the covered
person;
(ii) Standard health care
services or treatments are not medically appropriate for the covered person;
or
(iii) There is no available
standard health care service or treatment covered by the health carrier that is
more beneficial than the recommended or requested health care service or
treatment described in subparagraph (d) of this paragraph;
(d) The covered person's treating physician:
(i) Has recommended a health care service or
treatment that the physician certifies, in writing, is likely to be more
beneficial to the covered person, in the physician's opinion, than any
available standard health care services or treatments; or
(ii) Who is a licensed, board certified or
board eligible physician qualified to practice in the area of medicine
appropriate to treat the covered person's condition, has certified in writing
that scientifically valid studies using accepted protocols demonstrate that the
health care service or treatment requested by the covered person that is the
subject of the adverse determination or final adverse determination is likely
to be more beneficial to the covered person than any available standard health
care services or treatments;
(e) The covered person has exhausted the
health carrier's internal appeal process unless the covered person is not
required to exhaust the health carrier's internal appeal process pursuant to
Section (7) of this Rule; and
(f)
The covered person has provided all the information and forms required by the
Commissioner that are necessary to process an external review, including the
release form provided under Section (5)(B) of this Rule.
C.
(1) Within one (1) business day after
completion of the preliminary review, the health carrier shall notify the
Commissioner and the covered person and, if applicable, the covered person's
authorized representative in writing whether:
(a) The request is complete; and
(b) The request is eligible for external
review.
(2) If the
request:
(a) Is not complete, the health
carrier shall inform in writing the Commissioner and the covered person and, if
applicable, the covered person's authorized representative and include in the
notice what information or materials are needed to make the request complete;
or
(b) Is not eligible for external
review, the health carrier shall inform the covered person, the covered
person's authorized representative, if applicable, and the Commissioner in
writing and include in the notice the reasons for its ineligibility.
(3)
(a) The Commissioner may specify the form for
the health carrier's notice of initial determination under (C)(2) of this
Section and any supporting information to be included in the notice by
bulletin, directive or other publication to health carriers.
(b) The notice of initial determination
provided under (C)(2) of this Section shall include a statement informing the
covered person and, if applicable, the covered person's authorized
representative that a health carrier's initial determination that the external
review request is ineligible for review may be appealed to the
Commissioner.
(4)
(a) The Commissioner may determine that a
request is eligible for external review notwithstanding a health carrier's
initial determination that the request is ineligible and require that it be
referred for external review.
(b)
In making a determination under (C)(4)(a), the Commissioner's decision shall be
made in accordance with the terms of the covered person's health benefit plan
and shall be subject to all applicable provisions of this Rule.
(5) Whenever a request for
external review is determined eligible for external review, the health carrier
shall notify the Commissioner and the covered person and, if applicable, the
covered person's authorized representative.
D.
(1)
Within one (1) business day after the receipt of the notice from the health
carrier that the external review request is eligible for external review
pursuant to (A)(2)(d) or (C)(5) of this Section, the Commissioner shall:
(a) Assign an independent review organization
to conduct the external review from the list of approved independent review
organizations compiled and maintained by the commissioner pursuant to Section
(12) of this Rule and notify the health carrier of the name of the assigned
independent review organization; and
(b) Notify in writing the covered person and,
if applicable, the covered person's authorized representative of the request's
eligibility and acceptance for external review.
(2) The Commissioner shall include in the
notice provided to the covered person and, if applicable, the covered person's
authorized representative a statement that the covered person or the covered
person's authorized representative may submit in writing to the assigned
independent review organization within five (5) business days following the
date of receipt of the notice provided pursuant to (D)(1) of this Section
additional information that the independent review organization shall consider
when conducting the external review. The independent review organization is not
required to, but may, accept and consider additional information submitted
after five (5) business days.
(3)
Within one (1) business day after the receipt of the notice of assignment to
conduct the external review pursuant to (D)(1) under this Section, the assigned
independent review organization shall:
(a)
Select one or more clinical reviewers, as it determines is appropriate,
pursuant to (D)(4) of this Section to conduct the external review;
and
(b) Based on the opinion of the
clinical reviewer, or opinions if more than one clinical reviewer has been
selected to conduct the external review, make a decision to uphold or reverse
the adverse determination or final adverse determination.
(4)
(a) In
selecting clinical reviewers pursuant to (D)(3)(a) of this Section, the
assigned independent review organization shall select physicians or other
health care professionals who meet the minimum qualifications described in
Section (13) of this Rule and, through clinical experience in the past three
(3) years, are experts in the treatment of the covered person's condition and
knowledgeable about the recommended or requested health care service or
treatment.
(b) Neither the covered
person, the covered person's authorized representative, if applicable, nor the
health carrier shall choose or control the choice of the physicians or other
health care professionals to be selected to conduct the external
review.
(5) In
accordance with Subsection (H) of this Section, each clinical reviewer shall
provide a written opinion to the assigned independent review organization on
whether the recommended or requested health care service or treatment should be
covered.
(6) In reaching an
opinion, clinical reviewers are not bound by any decisions or conclusions
reached during the health carrier's utilization review procedure or the health
carrier's internal appeal procedure.
E.
(1)
Within five (5) business days after the date of receipt of the notice provided
pursuant to (D)(1) of this Section, the health carrier or its designee
utilization review organization shall provide to the assigned independent
review organization, the documents and any information considered in making the
adverse determination or the final adverse determination.
(2) Except as provided in (E)(3) under this
Section, failure by the health carrier or its designee utilization review
organization to provide the documents and information within the time specified
in (E)(1) shall not delay the conduct of the external review.
(3)
(a) If
the health carrier or its designee utilization review organization has failed
to provide the documents and information within the time specified in (E)(1) in
this Section, the assigned independent review organization may terminate the
external review and make a decision to reverse the adverse determination or
final adverse determination.
(b)
Immediately upon making the decision under (E)(3)(a) of this Section, the
independent review organization shall notify the covered person, the covered
person's authorized representative, if applicable, the health carrier, and the
Commissioner.
F.
(1) Each
clinical reviewer selected pursuant to Subsection (D) under this Section shall
review all of the information and documents received pursuant to Subsection (E)
of this Section and any other information submitted in writing by the covered
person or the covered person's authorized representative pursuant to (D)(2) of
this Section.
(2) Upon receipt of
any information submitted by the covered person or the covered person's
authorized representative pursuant to subsection (D)(2) of this Section, within
one (1) business day after the receipt of the information, the assigned
independent review organization shall forward the information to the health
carrier.
G.
(1) Upon receipt of the information required
to be forwarded pursuant to Subsection (F)(2) of this Section, the health
carrier may reconsider its adverse determination or final adverse determination
that is the subject of the external review.
(2) Reconsideration by the health carrier of
its adverse determination or final adverse determination pursuant to (G)(1) of
this Section shall not delay or terminate the external review.
(3) The external review may terminated only
if the health carrier decides, upon completion of its reconsideration, to
reverse its adverse determination or final adverse determination and provide
coverage or payment for the recommended or requested health care service or
treatment that is the subject of the adverse determination or final adverse
determination.
(4)
(a) Immediately upon making the decision to
reverse its adverse determination or final adverse determination, as provided
in (G)(3) of this Section, the health carrier shall notify the covered person,
the covered person's authorized representative if applicable, the assigned
independent review organization, and the commissioner in writing of its
decision.
(b) The assigned
independent review organization shall terminate the external review upon
receipt of the notice from the health carrier sent pursuant to (G)(4)(a) of
this Section.
H.
(1)
Except as provided in (H)(3) of this Section, within twenty (20) days after
being selected in accordance with Subsection (D) of this Section to conduct the
external review, each clinical reviewer shall provide an opinion to the
assigned independent review organization pursuant to subsection I on whether
the recommended or requested health care service or treatment should be
covered.
(2) Except for an opinion
provided pursuant to (H)(3) of this Section, each clinical reviewer's opinion
shall be in writing and include the following information:
(a) A description of the covered person's
medical condition;
(b) A
description of the indicators relevant to determining whether there is
sufficient evidence to demonstrate that the recommended or requested health
care service or treatment is more likely than not to be beneficial to the
covered person than any available standard health care services or treatments
and the adverse risks of the recommended or requested health care service or
treatment would not be substantially increased over those of available standard
health care services or treatments;
(c) A description and analysis of any medical
or scientific evidence, as that term is defined in Section (3)(DD) of this
Rule, considered in reaching the opinion;
(d) A description and analysis of any
evidence-based standard, as that term is defined in Section (3)(S) of this
Rule; and
(e) Information on
whether the reviewer's rationale for the opinion is based on (I)(5)(a) or (b)
of this Section.
(3)
(a) For an expedited external review, each
clinical reviewer shall provide an opinion orally or in writing to the assigned
independent review organization as expeditiously as the covered person's
medical condition or circumstance requires, but in no event more than five (5)
calendar days after being selected in accordance with Subsection (D) of this
Section.
(b) If the opinion
provided pursuant to (H)(3)(a) of this Section was not in writing, within
forty-eight (48) hours following the date the opinion was provided, the
clinical reviewer shall provide written confirmation of the opinion to the
assigned independent review organization and include the information required
under (H)(2) of this Section.
I. In addition to the documents and
information provided pursuant to (A)(2) or (E) of this Section, each clinical
reviewer selected pursuant to Subsection (D) of this Section, to the extent the
information or documents are available and the reviewer considers appropriate,
shall consider the following in reaching an opinion pursuant to Subsection (H)
of this Section:
(1) The covered person's
pertinent medical records;
(2) The
attending physician or health care professional's recommendation;
(3) Consulting reports from appropriate
health care professionals and other documents submitted by the health carrier,
covered person, the covered person's authorized representative, or the covered
person's treating physician or health care professional;
(4) The terms of coverage under the covered
person's health benefit plan with the health carrier to ensure that, but for
the health carrier's determination that the recommended or requested health
care service or treatment that is the subject of the opinion is experimental or
investigational, the reviewer's opinion is not contrary to the terms of
coverage under the covered person's health benefit plan with the health
carrier; and
(5) Whether:
(a) The recommended or requested health care
service or treatment has been approved by the federal Food and Drug
Administration, if applicable, for the condition; or
(b) Medical or scientific evidence or
evidence-based standards demonstrate that the expected benefits of the
recommended or requested health care service or treatment is more likely than
not to be beneficial to the covered person than any available standard health
care service or treatment and the adverse risks of the recommended or requested
health care service or treatment would not be substantially increased over
those of available standard health care services or treatments.
J.
(1)
(a)
Except as provided in (J)(1)(b) of this Section, within twenty (20) days after
the date it receives the opinion of each clinical reviewer pursuant to
Subsection (I) of this Section, the assigned independent review organization,
in accordance with (J)(2) of this Section, shall make a decision and provide
written notice of the decision to:
(i) The
covered person;
(ii) If applicable,
the covered person's authorized representative;
(iii) The health carrier; and
(iv) The Commissioner.
(b)
(i) For
an expedited external review, within seventy- two (72) hours after the date it
receives the opinion of each clinical reviewer pursuant to Subsection (I) under
this Section, the assigned independent review organization, in accordance with
(J)(2) of this Section, shall make a decision and provide notice of the
decision orally or in writing to the persons listed in (J)(1)(a) under this
Section.
(ii) If the notice
provided under (J)(b)(i) under this Section was not in writing, within
forty-eight (48) hours after the date of providing that notice, the assigned
independent review organization shall provide written confirmation of the
decision to the persons listed in (J)(1)(a) of this Section and include the
information set forth in (J)(3).
(2)
(a) If
a majority of the clinical reviewers recommend that the recommended or
requested health care service or treatment should be covered, the independent
review organization shall make a decision to reverse the health carrier's
adverse determination or final adverse determination.
(b) If a majority of the clinical reviewers
recommend that the recommended or requested health care service or treatment
should not be covered, the independent review organization shall make a
decision to uphold the health carrier's adverse determination or final adverse
determination.
(c)
(i) If the clinical reviewers are evenly
split as to whether the recommended or requested health care service or
treatment should be covered, the independent review organization shall obtain
the opinion of an additional clinical reviewer in order for the independent
review organization to make a decision based on the opinions of a majority of
the clinical reviewers pursuant to (J)(2)(a) or (J)(2)(b) of this
Section.
(ii) The additional
clinical reviewer selected under (J)(2)(c)(i) of this Section shall use the
same information to reach an opinion as the clinical reviewers who have already
submitted their opinions pursuant to Subsection (I) of this Section.
(iii) The selection of the additional
clinical reviewer under this subparagraph shall not extend the time within
which the assigned independent review organization is required to make a
decision based on the opinions of the clinical reviewers selected under
Subsection (D) of this Section.
(3) The independent review organization shall
include in the notice provided pursuant to (J)(1) of this Section:
(a) A general description of the reason for
the request for external review;
(b) The written opinion of each clinical
reviewer, including the recommendation of each clinical reviewer as to whether
the recommended or requested health care service or treatment should be covered
and the rationale for the reviewer's recommendation;
(c) The date the independent review
organization was assigned by the commissioner to conduct the external
review;
(d) The date the external
review was conducted;
(e) The date
of its decision;
(f) The principal
reason or reasons for its decision; and
(g) The rationale for its decision.
(4) Upon receipt of a notice of a
decision pursuant to (J)(1) of this Section reversing the adverse determination
or final adverse determination, the health carrier immediately shall approve
coverage of the recommended or requested health care service or treatment that
was the subject of the adverse determination or final adverse determination.
L. The assignment by
the Commissioner of an approved independent review organization to conduct an
external review in accordance with this Section shall be done on a random basis
among those approved independent review organizations qualified to conduct the
particular external review based on the nature of the health care service that
is the subject of the adverse determination or final adverse determination and
other circumstances, including conflict of interest concerns pursuant to
Section (13)(D) of this Rule.
Section 13.
Minimum Qualifications for
Independent Review Organizations
A. To
be approved under Section (12) of this Rule to conduct external reviews, an
independent review organization shall have and maintain written policies and
procedures that govern all aspects of both the standard external review process
and the expedited external review process set forth in this Rule that include,
at a minimum:
(1) A quality assurance
mechanism in place that:
(a) Ensures that
external reviews are conducted within the specified time frames and required
notices are provided in a timely manner;
(b) Ensures the selection of qualified and
impartial clinical reviewers to conduct external reviews on behalf of the
independent review organization and suitable matching of reviewers to specific
cases and that the independent review organization employs or contracts with an
adequate number of clinical reviewers to meet this objective;
(c) Ensures the confidentiality of medical
and treatment records and clinical review criteria; and
(d) Ensures that any person employed by or
under contract with the independent review organization adheres to the
requirements of this Rule;
(2) A toll-free telephone service to receive
information on a 24-hour-day, 7-day-a-week basis related to external reviews
that is capable of accepting, recording or providing appropriate instruction to
incoming telephone callers during other than normal business hours;
and
(3) Agree to maintain and
provide to the Commissioner the information set out in Section (15) of this
Rule.
B. All clinical
reviewers assigned by an independent review organization to conduct external
reviews shall be physicians or other appropriate health care providers who meet
the following minimum qualifications:
(1) Be
an expert in the treatment of the covered person's medical condition that is
the subject of the external review;
(2) Be knowledgeable about the recommended
health care service or treatment through recent or current actual clinical
experience treating patients with the same or similar medical condition of the
covered person;
(3) Hold a
non-restricted license in a State of the United States and, for physicians, a
current certification by a recognized American medical specialty board in the
area or areas appropriate to the subject of the external review; and
(4) Have no history of disciplinary actions
or sanctions, including loss of staff privileges or participation restrictions,
that have been taken or are pending by any hospital, governmental agency or
unit, or regulatory body that raise a substantial question as to the clinical
reviewer's physical, mental or professional competence or moral
character.
C. In
addition to the requirements set forth in Subsection (A) of this Section, an
independent review organization may not own or control, be a subsidiary of or
in any way be owned or controlled by, or exercise control with a health benefit
plan, a national, State or local trade association of health benefit plans, or
a national, State or local trade association of health care
providers.
D.
(1) In addition to the requirements set forth
in Subsections (A), (B) and (C) of this Section, to be approved pursuant to
Section (12) of this Rule to conduct an external review of a specified case,
neither the independent review organization selected to conduct the external
review nor any clinical reviewer assigned by the independent organization to
conduct the external review may have a material professional, familial or
financial conflict of interest with any of the following:
(a) The health carrier that is the subject of
the external review;
(b) The
covered person whose treatment is the subject of the external review or the
covered person's authorized representative;
(c) Any officer, director or management
employee of the health carrier that is the subject of the external
review;
(d) The health care
provider, the health care provider's medical group or independent practice
association recommending the health care service or treatment that is the
subject of the external review;
(e)
The facility at which the recommended health care service or treatment would be
provided; or
(f) The developer or
manufacturer of the principal drug, device, procedure or other therapy being
recommended for the covered person whose treatment is the subject of the
external review.
(2) In
determining whether an independent review organization or a clinical reviewer
of the independent review organization has a material professional, familial or
financial conflict of interest for purposes of paragraph (1), the Commissioner
shall take into consideration situations where the independent review
organization to be assigned to conduct an external review of a specified case
or a clinical reviewer to be assigned by the independent review organization to
conduct an external review of a specified case may have an apparent
professional, familial or financial relationship or connection with a person
described in (D)(1) of this Section, but that the characteristics of that
relationship or connection are such that they are not a material professional,
familial or financial conflict of interest that results in the disapproval of
the independent review organization or the clinical reviewer from conducting
the external review.
E.
(1) An independent review organization that
is accredited by a nationally recognized private accrediting entity that has
independent review accreditation standards that the commissioner has determined
are equivalent to or exceed the minimum qualifications of this section shall be
presumed in compliance with this section to be eligible for approval under
Section (12) of this Rule.
(2) The
Commissioner shall initially review and periodically review the independent
review organization accreditation standards of a nationally recognized private
accrediting entity to determine whether the entity's standards are, and
continue to be, equivalent to or exceed the minimum qualifications established
under this section. The commissioner may accept a review conducted by the NAIC
for the purpose of the determination under this paragraph.
(3) Upon request, a nationally recognized
private accrediting entity shall make its current independent review
organization accreditation standards available to the Commissioner or the NAIC
in order for the commissioner to determine if the entity's standards are
equivalent to or exceed the minimum qualifications established under this
section. The commissioner may exclude any private accrediting entity that is
not reviewed by the NAIC.
F. An independent review organization shall
be unbiased. An independent review organization shall establish and maintain
written procedures to ensure that it is unbiased in addition to any other
procedures required under this section.